Suppr超能文献

靶向心肌驻留CCR2+巨噬细胞分泌的MCP-1以减轻心肌梗死后的炎症反应。

Targeting cardiac resident CCR2+ macrophage-secreted MCP-1 to attenuate inflammation after myocardial infarction.

作者信息

Wen Jiaxing, Guan Ya, Niu Hong, Dang Yu, Guan Jianjun

机构信息

Institute of Materials Science and Engineering, Washington University in St. Louis. St. Louis, MO 63130, USA.

Department of Mechanical Engineering and Materials Science, Washington University in St. Louis. St. Louis, MO 63130, USA.

出版信息

Acta Biomater. 2024 Aug 23. doi: 10.1016/j.actbio.2024.08.025.

Abstract

After myocardial infarction (MI), cardiac resident CCR2+ macrophages release various cytokines and chemokines, notably monocyte chemoattractant protein-1 (MCP-1). MCP-1 is instrumental in recruiting CCR2+ monocytes to the damaged region. The excessive arrival of these monocytes, which then become macrophages, perpetuates inflammation at the site of injury. This continuous inflammation leads to adverse tissue remodeling and compromises cardiac function over time. We hypothesized that neutralizing the MCP-1 secreted by cardiac resident CCR2+ macrophages can mitigate post-MI inflammation by curtailing the recruitment of monocytes and their differentiation into macrophages. In this work, we developed nanoparticles that target the infarcted heart, specifically accumulating in the damaged area after intravenous (IV) administration, and docking onto CCR2+ macrophages. These nanoparticles were designed to slowly release an MCP-1 binding peptide, HSWRHFHTLGGG (HSW), which neutralizes the upregulated MCP-1. We showed that the HSW reduced monocyte migration, inhibited pro-inflammatory cytokine upregulation, and suppressed myofibroblast differentiation in vitro. After IV delivery, the released HSW significantly decreased monocyte recruitment and pro-inflammatory macrophage density, increased cardiac cell survival, attenuated cardiac fibrosis, and improved cardiac function. Taken together, our findings support the strategy of MCP-1 neutralization at the acute phase of MI as a promising way to alleviate post-MI inflammation. STATEMENT OF SIGNIFICANCE: After a myocardial infarction (MI), CCR2+ macrophages resident in the heart release various cytokines and chemokines, notably monocyte chemoattractant protein-1 (MCP-1). MCP-1 is instrumental in attracting CCR2+ monocytes to the damaged region. The excessive arrival of these monocytes, which then become macrophages, perpetuates inflammation at the site of injury. This continuous inflammation leads to adverse tissue remodeling and compromises cardiac function over time. In this work, we tested the hypothesis that neutralizing the MCP-1 secreted by cardiac CCR2+ macrophages can mitigate post-MI inflammation by curtailing the recruitment of monocytes.

摘要

心肌梗死(MI)后,心脏驻留的CCR2⁺巨噬细胞会释放多种细胞因子和趋化因子,尤其是单核细胞趋化蛋白-1(MCP-1)。MCP-1有助于将CCR2⁺单核细胞募集到受损区域。这些单核细胞过度聚集,随后转变为巨噬细胞,使损伤部位的炎症持续存在。这种持续的炎症会导致不良的组织重塑,并随着时间的推移损害心脏功能。我们推测,中和心脏驻留的CCR2⁺巨噬细胞分泌的MCP-1,可以通过减少单核细胞的募集及其向巨噬细胞的分化来减轻心肌梗死后的炎症。在这项研究中,我们开发了靶向梗死心脏的纳米颗粒,静脉注射(IV)后能特异性地在受损区域积聚,并与CCR2⁺巨噬细胞结合。这些纳米颗粒被设计用于缓慢释放一种MCP-1结合肽HSWRHFHTLGGG(HSW),以中和上调的MCP-1。我们发现,HSW在体外可减少单核细胞迁移、抑制促炎细胞因子上调并抑制成肌纤维细胞分化。静脉注射后,释放的HSW显著减少单核细胞募集和促炎巨噬细胞密度,增加心脏细胞存活率,减轻心脏纤维化,并改善心脏功能。综上所述,我们的研究结果支持在心肌梗死急性期中和MCP-1这一策略,认为这是减轻心肌梗死后炎症的一种有前景的方法。重要意义声明:心肌梗死(MI)后,心脏驻留的CCR2⁺巨噬细胞会释放多种细胞因子和趋化因子,尤其是单核细胞趋化蛋白-1(MCP-1)。MCP-1有助于将CCR2⁺单核细胞吸引到受损区域。这些单核细胞过度聚集,随后转变为巨噬细胞,使损伤部位的炎症持续存在。这种持续的炎症会导致不良的组织重塑,并随着时间的推移损害心脏功能。在这项研究中,我们验证了中和心脏CCR2⁺巨噬细胞分泌的MCP-1可以通过减少单核细胞募集来减轻心肌梗死后炎症的假设。

相似文献

4
Different Roles of Resident and Non-resident Macrophages in Cardiac Fibrosis.
Front Cardiovasc Med. 2022 Mar 7;9:818188. doi: 10.3389/fcvm.2022.818188. eCollection 2022.
6
Monocytes prime autoreactive T cells after myocardial infarction.
Am J Physiol Heart Circ Physiol. 2020 Jan 1;318(1):H116-H123. doi: 10.1152/ajpheart.00595.2019. Epub 2019 Dec 6.
8
Effect of CCR2 inhibitor-loaded lipid micelles on inflammatory cell migration and cardiac function after myocardial infarction.
Int J Nanomedicine. 2018 Oct 15;13:6441-6451. doi: 10.2147/IJN.S178650. eCollection 2018.
9
M2 Macrophage-Derived sEV Regulate Pro-Inflammatory CCR2 Macrophage Subpopulations to Favor Post-AMI Cardiac Repair.
Adv Sci (Weinh). 2023 May;10(14):e2202964. doi: 10.1002/advs.202202964. Epub 2023 Mar 22.

引用本文的文献

1
Advancements in nanomedicine for modulating ischemic cardiomyopathy therapy.
Mater Today Bio. 2025 Aug 23;34:102238. doi: 10.1016/j.mtbio.2025.102238. eCollection 2025 Oct.
2
Targeted delivery of engineered adipose-derived stem cell secretome to promote cardiac repair after myocardial infarction.
J Control Release. 2025 Jul 10;383:113765. doi: 10.1016/j.jconrel.2025.113765. Epub 2025 Apr 22.
3
Inflammatory Cell-Targeted Delivery Systems for Myocardial Infarction Treatment.
Bioengineering (Basel). 2025 Feb 19;12(2):205. doi: 10.3390/bioengineering12020205.

本文引用的文献

1
Co-Delivery of Bioengineered Exosomes and Oxygen for Treating Critical Limb Ischemia in Diabetic Mice.
ACS Nano. 2023 Dec 26;17(24):25157-25174. doi: 10.1021/acsnano.3c08088. Epub 2023 Dec 8.
4
PLGA nanoparticle preparations by emulsification and nanoprecipitation techniques: effects of formulation parameters.
RSC Adv. 2020 Jan 27;10(8):4218-4231. doi: 10.1039/c9ra10857b. eCollection 2020 Jan 24.
6
Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association.
Circulation. 2022 Feb 22;145(8):e153-e639. doi: 10.1161/CIR.0000000000001052. Epub 2022 Jan 26.
9
Myofibroblasts and Fibrosis: Mitochondrial and Metabolic Control of Cellular Differentiation.
Circ Res. 2020 Jul 17;127(3):427-447. doi: 10.1161/CIRCRESAHA.120.316958. Epub 2020 Jul 16.
10
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.
Circ Res. 2020 Apr 24;126(9):1260-1280. doi: 10.1161/CIRCRESAHA.120.315937. Epub 2020 Apr 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验